- > Media & Investors
- > Media Relations
- > Press Releases
- > Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017
For Immediate Release
Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: George Nakayama, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Noriaki Ishida, Executive Officer,
Vice President, Corporate Communications Department
Daiichi Sankyo Announces Organizational Restructuring Effective as of April 1, 2017
TOKYO, Japan (February 24, 2017) – Daiichi Sankyo Company, Limited, today announced the following organizational changes taking place from April 1,2017.
1．Daiichi Sankyo Co., Ltd.
In order to accelerate the advancement of the Daiichi Sankyo Cancer Enterprise and strengthen our product portfolio management, “Global Brand Strategy Division,” will be newly established with the “Global Specialty & Value Products Marketing” and “Intellectual Property” departments falling under it.
In order to strongly push forward the execution of the Daiichi Sankyo Group 5-year Business Plan, “Corporate Strategy Division” will newly be organized with the “Corporate Business Management,” “Finance and Accounting,” and “Corporate Communications” Departments.
Also, “General Affairs Division,” overseeing the “Human Resources,” “Corporate Affairs and Procurement,” “Legal Affairs,” “IT Strategy,” and “CSR” Departments will be formed.
Additionally, “Business Development & Licensing Department” will be moved under the President’s direct report with the intent of integrating global business development organizations.
Along with these changes, the existing “Corporate Strategy,” “Corporate Management,” and “General Affairs and Human Resources” Divisions, as well as the “Corporate Business Management” and “Corporate Strategy” Departments, will be dissolved.
(2) R&D Division
In order to strengthen our translational function between drug research and development, and to accelerate the development of personalized medicines, related functions will be gathered in the newly established, “Biomarker Department,” which falls under the Oncology Function.
“Translational Medicine & Clinical Pharmacology Department” will mainly specialize in the function of clinical pharmacology and be renamed, “Clinical Pharmacology Department.”
Along with the integration of the biologics and biomarker-related functions, the medicinal safety research and drug metabolism and pharmacokinetic research function, as well as research management functions, will be transferred to the current “Research Function,” and the “Research Technology Function” will be abolished.
(3) Biologics Division
“Biologics Division” will be newly established with the integration of biologics-related functions, including modality research, industrial science research, investigational product manufacturing, and commercial production functions.
Within “Biologics Division,” “Biologics Planning Department” will be formed and “Modality Research Laboratories” and “Cell Therapy Laboratories” from the R&D Division, as well as “Biologics Technology Research Laboratories” from the Pharmaceutical Technology Division, will be transferred to “Biologics Division.”
Furthermore, “Cell Therapy Laboratories” will be renamed, “Cell Therapy Research Laboratories.”
2．Daiichi Sankyo Healthcare Co., Ltd.
(1) Product Strategy Department
In order to strengthen the pipeline of products based on consumer needs, “Product Strategy Department” will be newly formed, containing the portfolio strategy and category/brand strategy functions, as well as product planning.
(2) Customer Satisfaction Department
To bring the VOC (Voice of Customer) into our product planning, related functions will be integrated to form “Customer Satisfaction Department”.